Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Receivables: 2012-2025

Historic Receivables for Adma Biologics (ADMA) over the last 11 years, with Sep 2025 value amounting to $137.7 million.

  • Adma Biologics' Receivables rose 174.58% to $137.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $396.8 million, marking a year-over-year increase of 152.27%. This contributed to the annual value of $50.0 million for FY2024, which is 82.34% up from last year.
  • Per Adma Biologics' latest filing, its Receivables stood at $137.7 million for Q3 2025, which was up 25.47% from $109.7 million recorded in Q2 2025.
  • Over the past 5 years, Adma Biologics' Receivables peaked at $137.7 million during Q3 2025, and registered a low of $15.4 million during Q1 2021.
  • Over the past 3 years, Adma Biologics' median Receivables value was $49.6 million (recorded in 2024), while the average stood at $59.0 million.
  • Its Receivables has fluctuated over the past 5 years, first tumbled by 45.74% in 2022, then skyrocketed by 264.38% in 2025.
  • Adma Biologics' Receivables (Quarterly) stood at $28.6 million in 2021, then tumbled by 45.74% to $15.5 million in 2022, then soared by 76.85% to $27.4 million in 2023, then soared by 82.34% to $50.0 million in 2024, then soared by 174.58% to $137.7 million in 2025.
  • Its Receivables was $137.7 million in Q3 2025, compared to $109.7 million in Q2 2025 and $99.4 million in Q1 2025.